肿瘤药学2019，Vol.9Issue(5)：754-757,762,5.DOI:10.3969/j.issn.2095-1264.2019.05.10
甲磺酸阿帕替尼治疗晚期乳腺癌的疗效及不良反应分析★
Analysis of Clinical Efficacy and Adverse Drug Reaction of Apatinib for Advanced Breast Cancer ★
摘要
Abstract
Objective To assess the clinical efficacy and safety of apatinib, a novel tyrosine inhibitor targeting vascular endothelial growth factor receptor-2, for patients with advanced breast cancer who had failed in second-line treatment. Methods Between Oct.2016 and Oct.2018, 62 cases of advanced breast cancer diagnosed by histopathology or cytology in Xuzhou Cancer Hospital were selected in this study. The 31 cases treated with routine chemotherapy were taken as control group, and 31 cases treated with routine chemotherapy together with apatinib mesylate tablets (taken orally 250~500 mg per day) were taken as observation group. Clinical efficacy and adverse reactions of apatinib mesylate tablets were evaluated at 4 weeks later until the disease progressed by comparing the differences of disease control rate (DCR), median progression-free survival (PFS) and various adverse reactions (ADR) between the two groups. Results All the 62 cases were measurable. The DCR of the observation group was higher than that of the control group (70.97% vs.38.71%, P<0.05). Median PFS of observation group was longer than that of the control group (7.7 months vs.5.6 months). For triple-negative breast cancer, the DCR of the observation group was higher than that of the control group (58.06% vs.29.03%, P<0.05); Median PFS of observation group was longer than that of the control group (6.2 months vs.5.5 months). The incidence and severity of hand-foot syndrome and elevation of blood pressure in the observation group were higher than those of the control group (hand-foot syndrome: 100% vs.25.81%, P<0.05; elevation of blood pressure:35.48% vs.12.90%). There was no statistically significant difference in the incidence of gastrointestinal system adverse reactions and bone marrow suppression between the two groups (P>0.05). Conclusion Apatinib could achieve good disease control rate and clinical benefits and controllable adverse reactions for advanced breast cancer patients who failed in second-line treatment.关键词
阿帕替尼/晚期乳腺癌/疗效/不良反应Key words
Apatinib mesylate/Advanced breast cancer/Clinical Efficacy/Adverse drug reaction分类
医药卫生引用本文复制引用
董栋,刘亚洲,李文广,孔蕴馨,唐会卓,王艳..甲磺酸阿帕替尼治疗晚期乳腺癌的疗效及不良反应分析★[J].肿瘤药学,2019,9(5):754-757,762,5.基金项目
江苏省卫计委资助项目(Y2015013). （Y2015013）
